MBX Biosciences (NASDAQ:MBX) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
MBX Biosciences (NASDAQ:MBX) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Assessing MBX Biosciences (MBX) Valuation After A 261% One Year Total Shareholder Return [Yahoo! Finance]
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]